
Metabolic bariatric surgery offers greater weight loss and lower costs than GLP-1 treatments for obesity, prompting a reevaluation of treatment strategies.

Kennedy Ferruggia is an assistant editor at Pharmacy Times®. She graduated from The College of New Jersey in 2023 in journalism and marketing. Prior to this position, she worked as a pharmacy associate for community pharmacies.

Metabolic bariatric surgery offers greater weight loss and lower costs than GLP-1 treatments for obesity, prompting a reevaluation of treatment strategies.

Gene therapy offers transformative potential in treating diseases like sickle cell and leukemia, highlighting pharmacists' crucial roles.

Gene therapy revolutionizes treatment in oncology, highlighting pharmacists' vital roles in patient care and long-term monitoring.

A real-world study at MSK reveals promising efficacy and safety of second-generation BTK inhibitors in mantle cell lymphoma treatment, influencing future guidelines.

Alice Wang, PharmD, BCOP, discusses the rapid infusion of isatuximab for multiple myeloma, highlighting its benefits, safety, and improved patient convenience in treatment.

Pharmacists lead the charge in integrating pharmacogenetics into patient care, overcoming education barriers and enhancing treatment outcomes through expert guidance.

New research reveals that eggs do not raise bad cholesterol; instead, saturated fat in the diet is the real culprit for heart disease.

Adam Kahleifeh, PharmD, BCOP, discusses the impact of IDH mutations in low-grade gliomas.

Mary Nauffal, PharmD, MS, BCOP, discusses innovative use of isatuximab for red cell aplasia post stem cell transplant, highlighting its potential in clinical trials.

Biolinq Shine, a wearable biosensor, revolutionizes diabetes management with real-time glucose, activity, and sleep tracking.

Xavier Leleu, MD, PhD, shares how OBI technology reduces preparation time and manual pushes for pharmacists.

Paltusotine, the first oral treatment for acromegaly, offers hope for improved patient care and management.

Expert shares the evolving role of pharmacy in patient care, emphasizing treatment accessibility and monitoring.

Pharmacists learn to recognize and combat burnout through self-awareness, open dialogue, and supportive workplace strategies for lasting well-being.

Pharmacists navigate the evolving hematology-oncology landscape, utilizing genetic insights and innovative therapies to enhance patient care.

Claudio Cerchione, MD, PhD, discusses the benefits of anti-CD38 quadruplet regimens for older patients with multiple myeloma.

Pharmacists navigate rapid oncology drug therapy changes, enhancing patient care through education, biomarker insights, and tailored counseling strategies.

Pharmacists contribute across direct patient care and education, adherence, and facilitating access.

Expert shares the promising potential of linvoseltamab in treating high-risk smoldering multiple myeloma.

Expert shares the latest advancements in CAR T therapy and novel treatments for myeloma, addressing access challenges and promising new options.

Older adults face heightened risks from RSV due to declining immunity and chronic conditions, making vaccination crucial for prevention and health.

Expert discusses groundbreaking studies on the on-body injector for isatuximab, highlighting its efficacy, safety, and patient convenience.

Pharmacists enhance patient care in multiple myeloma by focusing on infection prevention, CRS management, and optimizing outcomes with T-cell engagers post-CAR T.

Costimulatory bispecific antibodies revolutionize multiple myeloma treatment, offering deeper responses and flexible sequencing strategies for patients.

New findings reveal that combining daratumumab with lenalidomide significantly enhances MRD negativity and progression-free survival in multiple myeloma maintenance therapy.

Experts discuss the potential of linvoseltamab in treating high-risk smoldering multiple myeloma, highlighting promising early trial results and response rates.

Outpatient use of bispecifics and CAR T-cell therapies in multiple myeloma can expand access.

Teclistamab shows promising results in frontline multiple myeloma treatment, achieving high MRD negativity rates, but safety concerns remain.

An expert discusses the benefits of anti-CD38 quadruplet regimens for elderly multiple myeloma patients.

An expert discusses CAR T therapy's potential in treating relapsed multiple myeloma, highlighting long-term remissions and access challenges.